Preparation of 211At-labeled humanized anti-Tac using 211At produced in disposable internal and external bismuth targets

Nuclear Medicine and Biology

Volumn 25, Issue 2, 1998, Pages 89-93

  Schwarz, U P ^a,c   Plascjak, P ^b   Beitzel, M P ^a   Gansow, O A ^a   Eckelman, W C ^b   Waldmann, T A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Gesellensteig 15 D 38229   (Germany)

Author keywords

211At; Antibody fragments; Cyclotron production

Indexed keywords

ASTATINE 211; INTERLEUKIN 2 RECEPTOR; RADIOISOTOPE; ASTATINE; BISMUTH; RADIOPHARMACEUTICAL AGENT;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; CANCER RADIOTHERAPY; CYCLOTRON; DISTILLATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; RADIOACTIVITY; RADIOIMMUNOTHERAPY; CHEMISTRY; DRUG STABILITY; HUMAN; METABOLISM; METHODOLOGY; SYNTHESIS;

ASTATINE; BISMUTH; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOTRONS; DRUG STABILITY; HUMANS; ISOTOPE LABELING; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECEPTORS, INTERLEUKIN-2;

EID: 0031594529     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(97)00165-0     Document Type: Article

References (12)

1. Doberenz V., Dang D. N., Dreyer R., Milanov M., Norseyev Y. V., Hkalkin V. A. Preparation of astatine of high specific activity in solutions of a given composition. Radiochem. Radioanal. Lett. 52:1982;119-128.
2. Garg P. K., Garg S., Zalutsky M. R. N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate Synthesis and potential utility for the radioiodination of monoclonal antibodies . Nucl. Med. Biol. 20:1993;379-387.
3. 212Bi-anti-Tac. Cancer Res. 54:1994;4362-4370.
4. Kozak R. W., Atcher R. W., Gansow O. A., Friedman A. M., Hines J. J., Waldmann T. A. Bismuth-212-labeled anti-Tac monoclonal antibody α-particle-emitting radionuclides as modalities for radioimmunotherapy . Proc. Natl. Acad. Sci. USA. 83:1986;474-478.
5. Kozak R. W., Raubitschek A., Mirzadeh S., Brechbiel M. W., Junghaus R., Gansow O. A. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies Critical factors in determining in vivo survival and organ toxicity . Cancer Res. 49:1989;2639-2644.
6. Kreitman R., Bailon P., Chaudhar V., FitzGerald D., Pastan I. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood. 83:1994;426-434.
7. 211At reaction. Appl. Radiat. Isot. 47:1996;135-143.
8. Queen C., Schneider W. P., Selick H. E., Payne P. W., Landolfi N. F., Duncan J. F., Avdalovic N. M., Levitt M., Junghans R. P., Waldmann T. A. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA. 86:1989;10029-10033.
9. Waldmann T. A. Multichain interleukin-2 receptor A target for immunotherapy in lymphoma . J. Natl. Cancer Inst. 81:1989;914-923.
10. Waldmann T., Pastan I., Gansow O., Junghans R. The multichain interleukin-2 receptor A target for immunotherapy . Ann. Intern. Med. 116:1992;148-160.
11. Wilbur D., Hadley S., Hylarides M., Abrams P., Beaumier P., Morgan A., Reno J. Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer. J. Nucl. Med. 30:1989;216-226.
12. 2 fragments with the α-particle-emitting nuclide astatine-211 Preservation of immunoreactivity and in vivo localizing capacity . Proc. Natl. Acad. Sci. USA. 86:1989;7149-7153.